About this Research Topic
Dendritic cells have emerged as the most potent professional antigen-presenting cells capable of triggering adaptive immunity and bolstering innate immune responses, even in the absence of T cells. The past decade has witnessed a surge in research and development aimed at refining dendritic cell vaccine construction. With over 200 clinical trials targeting various malignancies such as melanoma, prostate cancer, glioblastoma, and renal cell carcinoma, significant strides have been made. Unlike many cytotoxic therapies, cancer vaccines have exhibited minimal toxicity in clinical trials, driving their continued utilization in patients with diverse cancer types. However, while DC immunotherapy holds immense promise, achieving tangible clinical outcomes remains a challenge in several trials, primarily due to immune suppression and/or tumor evasion mechanisms. Consequently, there is a pressing need to explore novel vaccine strategies to unlock the full potential of cancer immunotherapy.
A deeper understanding of the intricate dynamics within the tumor microenvironment holds the key to refining immunotherapeutic strategies for more effective and long-lasting control of tumor diseases. Numerous molecular and immunological factors, spanning from cancer cells to dendritic cells (DCs) to the broader patient-tumor interface, collectively influence the efficacy of DC vaccines. These include the characteristics and origins of tumor antigens, the composition of DC maturation cocktails, the influence of tumor burden and the immune microenvironment, as well as factors like the route, dosage, and timing of DC vaccination, and the overall immune health of patients. By unravelling these complexities, we can identify specific molecules and pathways that modulate the performance of dendritic cell subsets. Recent breakthroughs in comprehending dendritic cells, tumor antigens, and their complex interactions have unveiled promising prospects for crafting next-generation DC vaccines, particularly within adjuvant combinatorial therapy, tailored for specific cancer types. Despite lingering challenges, clear pathways for developing advanced DC vaccines have emerged offering a pool of advanced ideas aimed at not only enhancing therapeutic efficacy but also increase the application of immunotherapy for a diverse range of cancer patients.
This Research Topic accepts Original Research, Systematic Review, Review and Mini-Review, Policy and Practice Reviews, Hypothesis & Theory, Clinical Trial, Classification, Study Protocol, Perspective, Case Report, Brief Research Report, Data Report, General Commentary, Opinion.
We welcome manuscripts focusing on, but not limited to, the following sub-topics:
• Dendritic cell and cancer
• Dendritic cell based cancer vaccine
• Dendritic cells and combinatorial strategies
• Dendritic cell based cancer vaccines and combinatorial strategies
• Dendritic cell based cancer vaccine and ICI
• Next-generation DC vaccines
• Next-generation DC vaccines and Neoantigens
Topic Editor Zohreh Amoozgar is employed by Sanofi. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
A deeper understanding of the intricate dynamics within the tumor microenvironment holds the key to refining immunotherapeutic strategies for more effective and long-lasting control of tumor diseases. Numerous molecular and immunological factors, spanning from cancer cells to dendritic cells (DCs) to the broader patient-tumor interface, collectively influence the efficacy of DC vaccines. These include the characteristics and origins of tumor antigens, the composition of DC maturation cocktails, the influence of tumor burden and the immune microenvironment, as well as factors like the route, dosage, and timing of DC vaccination, and the overall immune health of patients. By unravelling these complexities, we can identify specific molecules and pathways that modulate the performance of dendritic cell subsets. Recent breakthroughs in comprehending dendritic cells, tumor antigens, and their complex interactions have unveiled promising prospects for crafting next-generation DC vaccines, particularly within adjuvant combinatorial therapy, tailored for specific cancer types. Despite lingering challenges, clear pathways for developing advanced DC vaccines have emerged offering a pool of advanced ideas aimed at not only enhancing therapeutic efficacy but also increase the application of immunotherapy for a diverse range of cancer patients.
This Research Topic accepts Original Research, Systematic Review, Review and Mini-Review, Policy and Practice Reviews, Hypothesis & Theory, Clinical Trial, Classification, Study Protocol, Perspective, Case Report, Brief Research Report, Data Report, General Commentary, Opinion.
We welcome manuscripts focusing on, but not limited to, the following sub-topics:
• Dendritic cell and cancer
• Dendritic cell based cancer vaccine
• Dendritic cells and combinatorial strategies
• Dendritic cell based cancer vaccines and combinatorial strategies
• Dendritic cell based cancer vaccine and ICI
• Next-generation DC vaccines
• Next-generation DC vaccines and Neoantigens
Topic Editor Zohreh Amoozgar is employed by Sanofi. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords: Dendritic cells, Immunotherapy, Cancer treatment, Combinatorial treatment, DC based cancer vaccine, ICI
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
